The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck; Merck; Merck; Merck
Speakers' Bureau - Astellas Pharma; Astellas Pharma; Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER
Research Funding - Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Roche (Inst); Roche (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER
Impact of baseline hepatitis B viremia and management on outcomes in patients (Pts) with advanced hepatocellular carcinoma (HCC) and elevated alpha-fetoprotein (AFP): Outcomes from REACH-2.
 
Peter R. Galle
Honoraria - Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; Sillajen; Sillajen; Sillajen; Sillajen; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Consulting or Advisory Role - Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Lilly; Lilly; Lilly; Lilly; MSD; MSD; MSD; MSD; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
Speakers' Bureau - Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Lilly; Lilly; Lilly; Lilly
Travel, Accommodations, Expenses - Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Lilly; Lilly; Lilly; Lilly; Sirtex Medical; Sirtex Medical; Sirtex Medical; Sirtex Medical
 
Masatoshi Kudo
Honoraria - Bayer; Bayer; Bayer; Bayer; Eisai; Eisai; Eisai; Eisai; MSD; MSD; MSD; MSD
Consulting or Advisory Role - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Research Funding - Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); Abbvie (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst); Takeda (Inst)
 
Josep M. Llovet
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Blueprint Medicines; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Can-Fite BioPharma; Can-Fite BioPharma; Can-Fite BioPharma; Can-Fite BioPharma; Celsion; Celsion; Celsion; Celsion; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Fortress Biotech; Fortress Biotech; Fortress Biotech; Fortress Biotech; Glycotest; Glycotest; Glycotest; Glycotest; Incyte; Incyte; Incyte; Incyte; Leerink; Leerink; Leerink; Leerink; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Midatech Pharma; Midatech Pharma; Midatech Pharma; Midatech Pharma; Navigant Consulting; Navigant Consulting; Navigant Consulting; Navigant Consulting; Nucleix; Nucleix; Nucleix; Nucleix; Spring Bank; Spring Bank; Spring Bank; Spring Bank
Research Funding - Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Bayer Schering Pharma (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst); Ipsen (Inst)
Travel, Accommodations, Expenses - Bayer; Bayer; Bayer; Bayer
 
Richard S. Finn
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Genentech/Roche; Genentech/Roche; Genentech/Roche; Genentech/Roche; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst); Roche/Genentech (Inst)
Expert Testimony - Novartis; Novartis; Novartis; Novartis
 
Mark Karwal
Consulting or Advisory Role - Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis
Research Funding - Merck; Merck; Merck; Merck
 
Denis Pezet
No Relationships to Disclose
 
Tae-You Kim
No Relationships to Disclose
 
Tsai-Sheng Yang
No Relationships to Disclose
 
Vittorina Zagonel
No Relationships to Disclose
 
Jiri Tomasek
Honoraria - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche; SERVIER; SERVIER; SERVIER; SERVIER
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Ipsen; Ipsen; Pfizer; Pfizer; Pfizer; Pfizer
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Ipsen; Ipsen; Ipsen; Ipsen; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Pfizer; Pfizer; Pfizer; Pfizer; Roche; Roche; Roche; Roche
 
Jean Marc Phelip
Honoraria - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER
Consulting or Advisory Role - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER
Research Funding - Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Roche; Roche; Roche; Roche; Sanofi; Sanofi; Sanofi; Sanofi; SERVIER; SERVIER; SERVIER; SERVIER
 
Yann Touchefeu
Consulting or Advisory Role - Bayer; Bayer; Bayer; Bayer; Merck Serono; Merck Serono; Merck Serono; Merck Serono
Travel, Accommodations, Expenses - Amgen; Amgen; Amgen; Amgen; Bayer; Bayer; Bayer; Bayer; BioCodex; BioCodex; BioCodex; BioCodex; Ipsen; Ipsen; Ipsen; Ipsen; Merck Serono; Merck Serono; Merck Serono; Merck Serono; Novartis; Novartis; Novartis; Novartis; Roche; Roche; Roche; Roche
 
Su-Jin Koh
No Relationships to Disclose
 
Guido Stirnimann
Consulting or Advisory Role - Alnylam; Alnylam; Alnylam; Alnylam; GMP-Orphan; GMP-Orphan; GMP-Orphan; GMP-Orphan; Intercept Pharmaceuticals; Intercept Pharmaceuticals; Intercept Pharmaceuticals; Intercept Pharmaceuticals; Sequana Medical; Sequana Medical; Sequana Medical; Sequana Medical
Research Funding - Bayer; Bayer; Bayer; Bayer; Intercept Pharmaceuticals; Intercept Pharmaceuticals; Intercept Pharmaceuticals; Intercept Pharmaceuticals
Travel, Accommodations, Expenses - Gilead Sciences; Gilead Sciences; Gilead Sciences; Gilead Sciences
 
Chunxiao Wang
Employment - Lilly; Lilly; Lilly; Lilly
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly
 
Kenyon Ogburn
Employment - Lilly; Lilly; Lilly; Lilly
Stock and Other Ownership Interests - Alexion Pharmaceuticals; Alexion Pharmaceuticals; Alexion Pharmaceuticals; Alexion Pharmaceuticals; Lilly; Lilly; Lilly; Lilly
 
Paolo Abada
Employment - Lilly; Lilly; Lilly; Lilly
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly
 
Ryan C. Widau
Employment - Lilly; Lilly; Lilly; Lilly
Stock and Other Ownership Interests - Lilly; Lilly; Lilly; Lilly
 
Andrew X. Zhu
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; AstraZeneca; Bayer; Bayer; Bayer; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Eisai; Eisai; Eisai; Eisai; Exelixis; Exelixis; Exelixis; Exelixis; Lilly; Lilly; Lilly; Lilly; Merck; Merck; Merck; Merck; Novartis; Novartis; Novartis; Novartis; Roche/Genentech; Roche/Genentech; Roche/Genentech; Roche/Genentech
Research Funding - Bayer (Inst); Bayer (Inst); Bayer (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst); Novartis (Inst)